Patients with peripheral artery disease (PAD) are at risk of major adverse cardiac and cerebrovascular events. There are no readily available risk scores that can accurately identify which patients are most likely to sustain an event, making it difficult to identify those who might benefit from more aggressive intervention. Thus, we aimed to develop a novel predictive model-using machine learning methods on electronic health record data-to identify which PAD patients are most likely to develop major adverse cardiac and cerebrovascular events.
N
inety-six percent of acute care hospitals in the United States have adopted electronic health record (EHR) technology as of 2015, up from just 9% in 2008. 1 Although billing and administrative tasks have been the focus of EHR systems, a large amount of granular, observational patient data offer unprecedented opportunities for data mining and analysis. In particular, the combination of advanced statistical methods and data volume provide an opportunity for stakeholders to build new technologies that can automate portions of health care, such as early detection of adverse drug reactions, predictions of in-hospital mortality, wound healing, and risk stratification for heart failure readmissions. [2] [3] [4] [5] Risk stratification using EHR data, in particular, has been of increasing interest for many investigators. 6 With only a limited number of well-validated risk-stratification scores, [7] [8] [9] [10] the use of EHR data from tens of thousands of patients may produce predictive models that can more accurately discriminate between patients at high and low risk of disease development or progression. However, as Goldstein et al 6 report in a meta-analysis of EHR-based risk-stratification models, researchers often do not take full advantage of the diversity of data available in the EHR. Frequently, model development will only use a handful of variables preemptively identified by investigators or only utilize coded data, such as lab values or diagnosis codes. This limitation in data usage may unduly limit the accuracy of predictive models, especially where complex nonlinear interactions are involved, even if the models are developed using data from thousands of patients.
In previous work, we demonstrated that using a database of patients with and without peripheral artery disease (PAD), machine learning algorithms could accurately identify patients with PAD who were previously undiagnosed. 11 Such approaches allow for the automatic identification of patients, require less active management by health care professionals directly, and can considerably shift the paradigm of health care delivery from a reactionary practice to a proactive one. 12, 13 Although this prior work demonstrated the ability to identify undiagnosed PAD patients, the data were derived from a well-structured prospectively collected database. Patients included in our predictive models had complete data across hundreds of phenotypic and genomic variables and were prospectively followed for years with accurate ascertainment of outcomes from hours of chart review and patient interviews and phone calls.
Real-world EHR data do not come as neatly packaged. Despite the volume, data may be missing or mislabeled, and patients may drop out of the data set at varying lengths of time. In the current work, we evaluate the feasibility of machine learning algorithms in identifying risk of future adverse cardiovascular events in patients diagnosed with PAD using EHR data. Note that when finding undiagnosed PAD patients, the disease in question is already present (but is unrecognized and untreated). For risk stratification, we use the portion of the record up to PAD diagnosis to predict the probability of the major adverse cardiac and cerebrovascular events' (MACCE) occurrence in the futuremaking it a much harder problem.
We hypothesized that, using observational EHR data and supervised machine learning, we would be able to learn predictive models that could accurately identify which PAD patients would go on to have MACCE before their occurrence. Accurate identification of patients at risk offers the possibility of managing highrisk patients differently. Therefore, accurate prediction is the first step towards personalized care, particularly when treatment alternatives exist.
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METHODS
Data Source
Data were derived from the EHR of 2 tertiary care hospitals. Only deidentified patient records were utilized, and the requirement for informed consent was waived. To ensure data deidentification, only pertinent clinical data without protected health information were extracted from the overall clinical data warehouse. Specifically, we extracted nonnegated terminology, codes, and results for each patient and used unique patient identifier codes. 15 Metadata, including dates and locations of visits (eg, inpatient, outpatient), were also retrieved and stored. Our Institutional Review Boards approved the study. Because of data privacy considerations, the clinical data are not available to researchers outside of our institutions for purposes of reproducing the results. However, the software used in these analyses are publicly available. 16, 17 
WHAT IS KNOWN
• Peripheral artery disease is a significant cause of cardiovascular disease morbidity and mortality.
• Risk assessment and medical optimization can increase longevity and decrease cardiovascular events in these patients.
• There are currently no well-validated methods for risk stratifying peripheral artery disease patients.
• Machine learning algorithms coupled with data from the electronic health record has potential to help clinicians rapidly risk stratify patients.
WHAT THE STUDY ADDS
• We present some of the latest methodologies for harnessing electronic health record data to predict patient outcomes.
• Machine learning algorithms perform well in identifying which peripheral artery disease patients will develop major adverse cardiac and cerebrovascular events in the future. 18 The CDM also allowed us to coerce enough structure into the EHR data to enable more efficient use of machine learning algorithms.
Common Data Model
A CDM allows for translation of different forms of observational data from different institutions into a cohesive database structure. This is achieved by defining broad concepts, their expected value units, and rules as to how similar concepts will be mapped into one unifying concept. For example, if "serum blood glucose" is used at one institution and "blood sugar" at another, they would fall into the broader category of blood glucose measurement in the CDM with units converted to mg/dL no matter what the initial units at each institution are. CDMs can thus allow for more rapid analysis of structured and unstructured data across multiple institutions.
Our text processing methodology allowed us to integrate unstructured clinical text into our CDM to utilize for predictive modeling. Details of our text processing pipeline are described in more detail in prior publications 19, 20 ; briefly, we utilized a strategy of identifying known medical terms within each clinical note within a patient's health record. We then mapped these terms to common medical concepts using standardized medical dictionaries. 21, 22 Terms that are ambiguous are removed, and terms that have similar meanings (eg, type 2 diabetes mellitus, insulin-dependent diabetes mellitus) are collapsed into 1 overriding concept. We then analyzed whether or not terms relate to the patient, or for instance family members, and if the term is negated. Terms that are unambiguous, relate to the patient, and are not negated are then tabulated for each patient ( Figure I in the Data Supplement). These terms are then further evaluated and integrated into the OMOP CDM along with coded data such as lab values, procedural codes, and diagnosis codes.
Study Population
Patients >18 years of age treated at SHC and MSSM with a diagnosis of PAD were included in the initial patient data cohort. Age was defined at time of entry into the health system. Patients had to have either an ICD-9 code or an affirmative text mention of PAD to be included. Please see Table II in the Data Supplement for concept definitions for PAD. Previous validation of this methodology for PAD identification demonstrated a specificity of 98% and precision of 83%. 23 Patients with MACCE, including stroke, acute myocardial infarction, severe cardiac arrhythmias, or sudden cardiac death, were also identified (Table II in the Data Supplement) using previously vetted MACCE concepts and ICD-9 codes. 23, 24 Positive examples (cases) for learning the model were defined as patients with PAD who had a MACCE outcome at least 30 days after PAD diagnosis.
Negative examples (controls) for the model were patients with a PAD diagnosis with no MACCE diagnosis before or after a PAD diagnosis. Data used in our prediction model included diagnosis codes, text data from notes, lab values, vital signs, and prescriptions extracted from the time of first presentation to SHC or MSSM up to and including the time of PAD diagnosis ( Figure 1 ). Thus, using the resulting model, a patient diagnosed with PAD could be risk stratified at time of diagnosis. Furthermore, we did not preselect cases or controls based on any prior evaluation of their risk of developing MACCE (eg, age or smoking status).
Patients were excluded if they had <1 year of data before PAD diagnosis to ensure enough data were available for predictive modeling. In the data we used, codes, notes, and results data were associated with specific encounter/visit dates (even during retrospective coding and billing procedures). This allowed us to ensure that adverse event data was not encoded with PAD diagnosis data as long as we specified that MACCE occurred on a date after PAD diagnosis. Patients were also excluded if <30 days of EHR data were available after PAD diagnosis to ensure that there was reasonable follow-up to exclude MACCE in control patients and also as another way to ensure MACCE and PAD diagnosis did not occur at or around the same time.
Missing data were not imputed in our data set. That is, if lab values, diagnosis codes, or observations were not reported for a patient, we did not attempt to predict their value or likelihood of absence or presence. If variables were present for one patient but not the other, an encoding of 0 indicated the variable's absence. The resulting data matrix, therefore, was relatively sparse. We did not impute data for 2 reasons. Our primary aim was to capture the performance of predictive modeling in real-world data, which will inherently include missing data. Second, there is no consensus as to which imputation methods are ideal for heterogeneous EHR data where data can be missing at random. 25 Thus, our results are reflective of the natural health care utilization patterns of each institution. Please see the Data Supplement for further discussion on the handling of missing data.
Study Design and Statistical Analysis
The goal of our study was to evaluate whether machine learning algorithms could analyze thousands of data points from the EHR to identify whether a patient with a new diagnosis of PAD would go on to have MACCE before the event occurrence. Our approach was to combine data from SHC and MSSM to create a more generalizable predictive model.
We used penalized linear regression and random forest algorithms to build our predictive models. Both algorithms have the ability to automatically select variables in a data set that provide the most predictive power. That is, instead of identifying lab values or diagnosis codes that we felt were most likely to help predict the outcome of interest, we included all EHR data from every patient at an institution and let the algorithm identify the variables to keep. However, data preprocessing becomes important in optimizing performance of machine learning algorithms. Our data preprocessing included normalizing data by number of patient visits. That is, features (disease mentions, ICD-9 codes, lab values, etc) were tabulated or averaged per patient then divided by the total number of visits over the course of the patient's observation window. Doing so allowed us to both adjust the scale of each data point to improve machine learning algorithm performance and ensure numeric stability by adjusting for any skewed numerical values. Normalization also allowed us to account for differences in length of patient records and provide relative weights for different variables. That is, if certain variables occurred more frequently in a patient record than others, their weight in the predictive algorithm would be higher than a less frequently occurring variable.
We performed nested cross-validation whereby model parameters and variable selection was done using an inner 5-fold cross-validation on a random sample of 75% of patients. The best-trained model was chosen based on the F-measure, balancing model precision and recall. Once the best model was selected, model performance was tested using an outer 5-fold cross-validation using the remaining 25% of patients. Model performance was judged both on its ability to discriminate between patients with a high and low risk of an outcome (ie, area under the receiver operating characteristic curve (area under the curve [AUC]) and its calibration (ie, ability to accurately quantify observed absolute risk). In addition to visual characterization of calibration, we also calculated the model Brier score. 26 We chose AUC and calibration as metrics to assess the best model, as opposed to other metrics such as Akaike information criterion because the former metrics can provide robust results using linear and nonlinear algorithms. 27 The best performing model was chosen as the final model. We used the Automated PHenotype Routine for Observational Definition, Identification, Training and Evaluation package from the Observational Health Data Sciences and Informatics group 16 and R version 3.2.1 for all data analyses.
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RESULTS
At SHC, we identified 9729 patients with PAD. After applying exclusion criteria, there were a total of 3577 patients remaining with 837 (23%) who had MACCE after PAD diagnosis and 2740 controls. Median time from initial presentation to SHC to diagnosis of PAD was 6.2 years (±4.7 years) for cases and median time of observation for control patients was 5.8 years (±5.2 years). Median time to MACCE for cases after PAD diagnosis was 2.2 years (±3 years).
The MSSM data set included 8259 PAD patients. A total of 4109 patients met inclusion criteria, of which 459 (12.6%) had MACCE after PAD diagnosis. Median time from initial presentation to MSSM to diagnosis of PAD was 5.3 years (±3.4 years) for cases, and median total observation time for controls was 4.4 years (±3.4 years). Median time to MACCE for cases after PAD diagnosis was 2.1 years (±3 years). The Table outlines differences in demographics, variable frequency, and outcomes across the 2 health care sites and between cases and controls.
Compared with a penalized linear regression algorithm, random forest performed significantly better overall (AUC, 0.69; 95% CI, 0.68-0.71 versus 0.81; 95% CI, 0.8-0.83; P<0.001, respectively). Our final model was a random forest model that utilized 957 variables. Figure 2 demonstrates the average AUC and calibration as produced by 5-fold outer cross-validation on the test set. Our model had overall good calibration (Brier score 0.10), although the model has a tendency to over-estimate risk for low-risk patients and underestimate risk for high-risk patients. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.5, 0.96, 0.8, and 0.9, respectively. These values correspond to thresholds obtained from the AUC plot with a true positive rate as close to 1 and a false positive rate as close to 0 as possible. Figure II in the Data Supplement illustrates the precision-recall curve, which demonstrates the trade-offs involved in increasing model sensitivity or specificity.
We performed sensitivity analysis on the best random forest model to evaluate how much each data type (unstructured text data, laboratory data, visit data (ICD-9 and Current Procedural Terminology codes) and prescriptions) contributed to the accuracy of the final model ( Figure 3) . We found that unstructured text and coded data added significantly to model performance. Removal of text data resulted in a drop in AUC from 0.81 to 0.78, P=0.002. Removal of coded data resulted in a decline in AUC to 0.77 (P=0.0004). To evaluate whether these differences were clinically significant, we calculated the net reclassification index and found that on average 20% of patients would be reclassified as higher or lower risk with the addition of text or coded data. Removing lab and prescription data did not result in significant changes in model discrimination. Lastly, in Table III in the Data Supplement, we provide the top 20 most important variables for each of the 5 outer crossvalidated test sets. Given that our data preprocessing included normalization using the number of patient visits, in addition to other predictive characteristics of each variable, the frequency of a variable's appearance may also contribute to their predictive importance. Myocardial infarction, n (%) 337 (40) 250 (54) Cardiac arrest/shock, n (%) 155 (18) 114 (25) Cardiac arrhythmia,* n (%) 143 (17) 30 (6) Stroke, n (%) 182 (22) 54 (12) Sudden death, n (%) 20 (2) 11 (2) MACCE indicates major adverse cardiac and cerebrovascular events. *Ventricular fibrillation or ventricular tachycardia.
rithms. Such a data analysis pipeline could potentially be deployed in real-time for personalized risk assessment for PAD patients and thus guide personalized treatment planning. Care for patients with chronic diseases, such as PAD, may be dramatically improved with use of automated, EHR-based technology. Patients with PAD often go undiagnosed in the primary care setting and are often not on optimal medical therapy. [28] [29] [30] [31] [32] [33] [34] With annual costs of PAD-related care estimated to be over $4 billion, better screening and treatment strategies are needed, especially in an era where health care systems are being tasked with efficiently providing care for regional populations. Particularly in the case of PAD, better risk stratification would allow for more aggressive risk factor mitigation efforts that include prescription of antiplatelets, high-dose cholesterol-lowering medications, more aggressive blood pressure management, and enrollment in smoking cessation programs. 30 What is more, with new Medicare reimbursement for supervised exercise programs and robust data showing improved outcomes with addition of rivaroxaban for stable PAD, 35 automated solutions to identify high-risk patients and increase awareness for new treatment options could substantially decrease cardiovascular morbidity and mortality.
To our knowledge, there are no current risk scores for MACCE in PAD patients. Although epidemiologically derived scores, such as the Framingham Risk Score, 36 can be of good clinical utility in identifying discrete clinical risk factors, these scores are developed and validated in such a way that their predictive accuracy do not always translate to different clinical contexts. The Framingham Risk Score, for example, was not developed specifically for PAD patients, and in our own experiments, we have found that even a recalibrated version of the Framingham Risk Score performs 20% to 25% worse than a machine-learned risk prediction model for MACCE. Thus, an advantage to using EHR data for risk prediction is that such models can be fine-tuned to local populations or more specific disease states and risk stratification can be automated. As an illustration of this, Arruda-Olson et al 37 describe their methodology of using EHR data to build a riskstratification model for 5-year mortality risk for PAD patients within their health system. By building a risk model specific to their patient population and extracting specific variables from the EHR, they achieve good discrimination and calibration and are able to provide results in real time.
Most published work evaluating EHR risk-stratification models show mixed results. 6 A majority of studies do not use longitudinal data, use relatively few predictive variables, with a median of 27 variables, and rarely develop multicenter models or validate models at different sites. A distinct strength of our work is that we used all variables available from the EHR, used longitudinal data from the patient's health records, and developed an accurate model by combining data from 2 distinct health care sites. In addition, we quantify the contribution of using features derived from unstructured and structured content, and we set up the study as a true prediction problem to build a risk model that can be used at the time of PAD diagnosis.
Our study highlights the immense utility of CDMs. Despite utilizing data from different institutions representing 2 geographically distinct hospital systems, with different payer mixes, patient populations with varying prevalence of disease (Table 1) , and different environmental risk factors, we were able to build a good prediction model for MACCE in the PAD population. In general, CDMs allow researchers to combine observational data sources from multiple institutions, which allows for data standardization and the ability to create analytical tools that can be applied broadly. There are 5 main CDMs for EHR currently in use in the United States, including OMOP. 18, [38] [39] [40] [41] [42] Although each CDM has a host of advantages and disadvantages, 43, 44 they are key to enabling big data analysis in health care for tasks, such as drug surveillance, 44, 45 comparative effectiveness research, 46 and reproducing EHR-based research results. 47 We show that a CDM is also useful for building risk predictive models.
Despite the accuracy of our findings, there are limitations to our work. First, despite an AUC of 0.81, the model sensitivity (maximizing the true positive and minimizing false positive rates) is 0.5, with a specificity of 0.96. Thus, cases identified using our predictive model are likely to be truly high-risk patients, but many patients may be missed. Models can be adjusted to provide more sensitivity by adjusting threshold cutoffs. The precision-recall curve ( Figure I in the Data Supplement) illustrates that increasing the sensitivity of the model to 100% would result in a drop in accuracy to <25%. This may be a reasonable trade-off in cases in which an intervention has a relatively low risk or low cost (eg, prescribing exercise therapy), but a higher specificity threshold would be warranted for higher risk interventions (eg, prescribing anticoagulation that may significantly increase bleeding risk).
Another limitation is that use of data across multiple institutions can potentially lead to less accurate predictive models as local data storage and mapping practices may differ, 48 as do patient populations. As detailed in Table for instance, the demographic mix at the 2 care sites are different. Furthermore, there are other clinical factors that may significantly vary across sites (eg, severity of cardiovascular disease, number of comorbidities, etc) as Stanford has twice the rate of MACCE as MSSM. These population and data differences may require that models be trained locally to obtain higher accuracy.
However, use of data from multiple institutions helps improve model generalizability as models trained on 1 specific data set have the risk of being over fitted with little applicability to other sites. We think that by using data from different institutions and by performing internal and external cross-validation, we have appropriately balanced model accuracy and generalizability. Nevertheless, our models may suffer from issues, such as overfitting, and only further testing at other institutions would better clarify our model's performance. What is more, in the effort to deliver precision health using institutional data some have advocated for data recalibration at different sites to maximize predictive model accuracy. 49 Need for recalibration is not necessarily a failure of our approach to predictive modeling because others have found that recalibrating more well-known epidemiologically derived risk scores provides better risk estimates for specific populations as well. 50 We also did not fully take into account missing data. Variables were included in the model if even 1 patient had a single value in the chart. This may have somewhat diminished our predictive accuracy; however, a strength of this approach is that it represents the true nature of live EHR data with minimal transformations and no data imputations. Given that we are not engaged in inference questions, but rather focus on building a predictor for risk stratification, 51, 52 we opt to use the data as they are. Another consideration is that we elected to define PAD and MACCE using diagnosis codes and term mentions because in our validation of this technique, we achieve an average specificity of 98% and precision of 90% across different cardiovascular disease states. 23 This methodology represents a more easily deployable solution to cohort building than natural language techniques, although there may be loss in sensitivity. Other techniques, such as using an objective ankle-brachial index measure, could also be pursued, although ankle-brachial indexes are not always available for review because at tertiary care centers, these exams are sometimes done at outside facilities and not adequately reported. Another limitation of our work is that given the fractured nature of health care in the United States, it is possible that we did not capture all MACCE cases as events. Although death data is integrated from the Social Security Death Index, other events may have occurred at other institutions without being reported to the index hospital of treatment. However, this issue would affect both the training and test sets of patients equally, and we still obtain reliable estimates of model performance. Such missing events do have the potential to reduce the overall performance of the model.
Another potential limitation that warrants discussion is our use of a black box algorithm for predicting MAC-CE in PAD patients. In medical research, our goals are often to understand causal pathways for diseases and outcomes or to predict their occurrence. Although similar statistical algorithms can be applied to these separate modeling tasks (prediction or inference), models that are good predictors of disease are not always models from which we can derive understanding of the disease mechanisms.
52,53 Because we did not force the use of any particular variables, the random forest algorithm found any variable in the EHR that was most associated with risk of future MACCE. The upside of such a model is that it can be more accurate than a simple linear regression model. However, the fact that the variables used are not always explanatory can be a drawback of this methodology. For example, higher age is associated with MACCE in the general population but might not be more associated with MACCE in the population with PAD. Therefore, when comparing equally aged PAD patients with equally aged non-PAD patients, age might not show up as predictive. Indeed in Table III in the Data Supplement, many of the predictive variables used in the random forest model, such as "assessment" or "chief complaint," cannot be used to understand why certain patients are at higher risk than others. Other traditional epidemiological approaches may be necessary to find causal links for disease risk in such cases where the variables used in a particular algorithm are not the most descriptive and may be more predictive of a pattern that produces increased risk rather than a specific, discrete risk factor. Even so, machine learning algorithms can be highly beneficial and may revolutionize our ability to deliver both precision and population health, especially with an understanding of the limitations of each algorithm. 54 For instance, associations between clinical, demographic, or imaging characteristics and patient outcomes are not always linear. Machine learning algorithms, such as random forest, are still able to identify nonlinear signals that can accurately predict disease occurrence and outcomes. 55 Such capabilities will become even more important as the depth and breadth of healthcare data grow. And while machine learning methodologies have many advantages, to truly improve patient care and outcomes, methods for teasing out causal relationships will remain an important part of the health care and biomedical armamentarium.
CONCLUSIONS
Machine learning algorithms using available data in the EHR can accurately predict which PAD patients are most likely to go on to develop MACCE. The use of a CDM enables de novo learning of accurate risk models across multiple sites. Such informatics approaches can be applied to the medical record in an automated fashion to risk stratify patients with vascular disease and identify those who might benefit from more aggressive disease management. Future evaluation of the prospective performance of machine learning techniques versus traditional risk scores could provide valuable understanding of the overall utility of a machine learning approach.
